Nothing Special   »   [go: up one dir, main page]

IL255228A0 - Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof - Google Patents

Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof

Info

Publication number
IL255228A0
IL255228A0 IL255228A IL25522817A IL255228A0 IL 255228 A0 IL255228 A0 IL 255228A0 IL 255228 A IL255228 A IL 255228A IL 25522817 A IL25522817 A IL 25522817A IL 255228 A0 IL255228 A0 IL 255228A0
Authority
IL
Israel
Prior art keywords
peptide
mhc complexes
constructs targeting
targeting hpv16
hpv16
Prior art date
Application number
IL255228A
Other languages
Hebrew (he)
Original Assignee
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eureka Therapeutics Inc filed Critical Eureka Therapeutics Inc
Publication of IL255228A0 publication Critical patent/IL255228A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL255228A 2015-05-08 2017-10-24 Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof IL255228A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562158735P 2015-05-08 2015-05-08
US201562197480P 2015-07-27 2015-07-27
PCT/US2016/031364 WO2016182957A1 (en) 2015-05-08 2016-05-06 Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof

Publications (1)

Publication Number Publication Date
IL255228A0 true IL255228A0 (en) 2017-12-31

Family

ID=57249446

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255228A IL255228A0 (en) 2015-05-08 2017-10-24 Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof

Country Status (12)

Country Link
EP (1) EP3294328A1 (en)
JP (1) JP2018516879A (en)
KR (1) KR20170141256A (en)
CN (1) CN107847570A (en)
AU (1) AU2016261356A1 (en)
CA (1) CA2988397A1 (en)
IL (1) IL255228A0 (en)
MX (1) MX2017014056A (en)
RU (1) RU2017142716A (en)
SG (1) SG11201708674XA (en)
TW (1) TW201713695A (en)
WO (1) WO2016182957A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059316A (en) 2015-10-23 2023-05-05 优瑞科生物技术公司 antibody/T cell receptor chimeric constructs and uses thereof
WO2018200582A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Chimeric antibody/t-cell receptor constructs and uses thereof
KR102702859B1 (en) 2017-06-28 2024-09-05 리제너론 파아마슈티컬스, 인크. Anti-human papillomavirus (HPV) antigen-binding protein and methods of use thereof
EP4215543A3 (en) 2017-10-03 2023-10-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
RU2750723C1 (en) * 2017-10-20 2021-07-01 Фармабцин Инк. Antibodies against vista and application thereof
WO2019195486A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
CN110776562B (en) * 2018-07-30 2022-06-17 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP antigen
CN113045655A (en) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 anti-OX 40 antibodies and uses thereof
CN115667302A (en) 2020-02-06 2023-01-31 亚洲大学校产学协力团 Fusion antibody for presenting antigen-derived T cell epitope or peptide containing the epitope on cell surface, and composition containing the fusion antibody
HRP20231031T1 (en) 2020-02-26 2023-12-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2
CN113321726B (en) * 2020-02-28 2024-05-28 香雪生命科学技术（广东）有限公司 T cell receptor for recognizing HPV
CN113801217A (en) * 2020-06-17 2021-12-17 香雪生命科学技术（广东）有限公司 High-affinity T cell receptor for recognizing HPV (human papilloma Virus) antigen
CN116635064A (en) 2020-12-18 2023-08-22 世纪治疗股份有限公司 Chimeric antigen receptor systems with adaptive receptor specificity
CN113637690A (en) * 2021-08-18 2021-11-12 武汉华美生物工程有限公司 Preparation method and application of human papilloma virus HPV16 type E7 active protein
WO2023133193A1 (en) * 2022-01-05 2023-07-13 Memorial Sloan-Kettering Cancer Center Anti-hpv antibodies and uses thereof
WO2024050399A1 (en) * 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304679A1 (en) * 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof

Also Published As

Publication number Publication date
TW201713695A (en) 2017-04-16
KR20170141256A (en) 2017-12-22
CA2988397A1 (en) 2016-11-17
WO2016182957A1 (en) 2016-11-17
CN107847570A (en) 2018-03-27
RU2017142716A (en) 2019-06-10
JP2018516879A (en) 2018-06-28
MX2017014056A (en) 2018-04-10
AU2016261356A1 (en) 2018-01-04
SG11201708674XA (en) 2017-11-29
EP3294328A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
IL287738A (en) Constructs targeting afp peptide/mhc complexes and uses thereof
HK1248255A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
IL255228A0 (en) Constructs targeting hpv16-e7 peptide/mhc complexes and uses thereof
IL258248A (en) Affinity-oligonucleotide conjugates and uses thereof
HK1244425A1 (en) Molecular constructs with targeting and effector elements
EP3380125A4 (en) Conjugates comprising peptide groups and methods related thereto
IL287825A (en) Sirp-alpha variant constructs and uses thereof
HK1231385A1 (en) Receptor targeting constructs and uses thereof
HK1248729A1 (en) Cytotoxic hexim1 peptides and uses thereof
IL256925A (en) Constructs targeting psa peptide/mhc complexes and uses thereof
IL258759A (en) Anti-cd3-folate conjugates and their uses
IL252902A0 (en) Amino acid and peptide conjugates and uses thereof
IL287985A (en) Koc1-derived peptide and vaccine including same
IL265236A (en) Therapeutic multi-targeting constructs and uses thereof
SG11201610918RA (en) Peptides and uses thereof